Semper Paratus Acquisition (LGSTW) Competitors

$0.03 0.00 (-2.79%)

As of 05/1/2026

LGSTW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does Semper Paratus Acquisition compare to Ainos?

Semper Paratus Acquisition (NASDAQ:LGSTW) and Ainos (NASDAQ:AIMDW) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

: Company Net Margins Return on Equity Return on Assets
Semper Paratus Acquisition N/A N/A N/A
Ainos N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semper Paratus Acquisition N/A N/A N/A N/A N/A
Ainos $124.16K N/A N/A N/A N/A
: In the previous week, Semper Paratus Acquisition's average media sentiment score of 0.00 equaled Ainos'average media sentiment score.
Company Overall Sentiment
Semper Paratus Acquisition Neutral
Ainos Neutral

Company	Net Margins	Return on Equity	Return on Assets
Semper Paratus Acquisition	N/A	N/A	N/A
Ainos	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
Ainos	$124.16K	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Semper Paratus Acquisition	Neutral
Ainos	Neutral

Summary

Ainos beats Semper Paratus Acquisition on 1 of the 1 factors compared between the two stocks.

How does Semper Paratus Acquisition compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Semper Paratus Acquisition (NASDAQ:LGSTW) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alvotech $586.32M N/A N/A N/A N/A
Semper Paratus Acquisition N/A N/A N/A N/A N/A
: Company Net Margins Return on Equity Return on Assets
Alvotech N/A N/A N/A
Semper Paratus Acquisition N/A N/A N/A
: In the previous week, Alvotech's average media sentiment score of 0.00 equaled Semper Paratus Acquisition'saverage media sentiment score.
Company Overall Sentiment
Alvotech Neutral
Semper Paratus Acquisition Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$586.32M	N/A	N/A	N/A	N/A
Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
Semper Paratus Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Alvotech	Neutral
Semper Paratus Acquisition	Neutral

Summary

Alvotech beats Semper Paratus Acquisition on 1 of the 1 factors compared between the two stocks.

How does Semper Paratus Acquisition compare to Aravive?

Semper Paratus Acquisition (NASDAQ:LGSTW) and Aravive (NASDAQ:ARAV) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

: 35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Company Net Margins Return on Equity Return on Assets
Semper Paratus Acquisition N/A N/A N/A
Aravive N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semper Paratus Acquisition N/A N/A N/A N/A N/A
Aravive N/A N/A N/A -$0.90 N/A
: In the previous week, Semper Paratus Acquisition's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.
Company Overall Sentiment
Semper Paratus Acquisition Neutral
Aravive Neutral

Company	Net Margins	Return on Equity	Return on Assets
Semper Paratus Acquisition	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

Company	Overall Sentiment
Semper Paratus Acquisition	Neutral
Aravive	Neutral

Summary

Aravive beats Semper Paratus Acquisition on 2 of the 2 factors compared between the two stocks.

How does Semper Paratus Acquisition compare to Atlantic Coastal Acquisition Corp. II?

Semper Paratus Acquisition (NASDAQ:LGSTW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both financial services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

: Company Net Margins Return on Equity Return on Assets
Semper Paratus Acquisition N/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Semper Paratus Acquisition N/A N/A N/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A
: In the previous week, Semper Paratus Acquisition's average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.
Company Overall Sentiment
Semper Paratus Acquisition Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Company	Net Margins	Return on Equity	Return on Assets
Semper Paratus Acquisition	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Semper Paratus Acquisition	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Summary

Semper Paratus Acquisition and Atlantic Coastal Acquisition Corp. II tied by winning 0 of the 0 factors compared between the two stocks.

How does Semper Paratus Acquisition compare to Avidity Biosciences?

Avidity Biosciences (NASDAQ:RNA) and Semper Paratus Acquisition (NASDAQ:LGSTW) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

: Semper Paratus Acquisition has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Semper Paratus Acquisition's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Avidity Biosciences -3,650.39% -44.92% -39.57%
Semper Paratus Acquisition N/A N/A N/A
: Semper Paratus Acquisition has lower revenue, but higher earnings than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
Semper Paratus Acquisition N/A N/A N/A N/A N/A
: In the previous week, Avidity Biosciences had 1 more articles in the media than Semper Paratus Acquisition. MarketBeat recorded 1 mentions for Avidity Biosciences and 0 mentions for Semper Paratus Acquisition. Avidity Biosciences' average media sentiment score of 0.00 equaled Semper Paratus Acquisition'saverage media sentiment score.
Company Overall Sentiment
Avidity Biosciences Neutral
Semper Paratus Acquisition Neutral
: Avidity Biosciences presently has a consensus target price of $69.42, suggesting a potential upside of 437.73%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than Semper Paratus Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
1 Sell rating(s)
12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
Semper Paratus Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%
Semper Paratus Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A
Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Avidity Biosciences	Neutral
Semper Paratus Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Semper Paratus Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Avidity Biosciences beats Semper Paratus Acquisition on 6 of the 9 factors compared between the two stocks.

Get Semper Paratus Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGSTW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGSTW vs. The Competition

Export

Metric	Semper Paratus Acquisition	Shell Companies Industry	Financial Sector	NASDAQ Exchange
Market Cap	N/A	$86.33M	$5.60B	$11.76B
Dividend Yield	N/A	5.35%	5.26%	5.26%
P/E Ratio	N/A	0.95	15.82	27.07
Price / Sales	N/A	286.16	975.33	73.43
Price / Cash	N/A	164.52	91.49	53.90
Price / Book	N/A	42.22	4.42	6.69
Net Income	N/A	-$131.69M	$1.15B	$332.64M
7 Day Performance	N/A	0.53%	1.11%	3.07%
1 Month Performance	N/A	0.51%	3.89%	7.80%
1 Year Performance	N/A	10.65%	21.52%	41.57%

Semper Paratus Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGSTW Semper Paratus Acquisition	N/A	$0.03 -2.8%	N/A	-26.9%	$0.00	N/A	N/A	3	Gap Down
AIMDW Ainos	N/A	$0.09 -17.7%	N/A	-65.4%	$0.00	$124.16K	N/A	40	Positive News
ALVOW Alvotech	N/A	$0.28 +29.4%	N/A	N/A	$0.00	$586.32M	N/A	4	Upcoming Earnings Gap Down
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGSTW) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Semper Paratus Acquisition (LGSTW) Competitors

LGSTW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does Semper Paratus Acquisition compare to Ainos?

Summary

How does Semper Paratus Acquisition compare to Alvotech?

Summary

How does Semper Paratus Acquisition compare to Aravive?

Summary

How does Semper Paratus Acquisition compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Semper Paratus Acquisition compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGSTW vs. The Competition

Semper Paratus Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Semper Paratus Acquisition (LGSTW) Competitors

LGSTW vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does Semper Paratus Acquisition compare to Ainos?

Summary

How does Semper Paratus Acquisition compare to Alvotech?

Summary

How does Semper Paratus Acquisition compare to Aravive?

Summary

How does Semper Paratus Acquisition compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Semper Paratus Acquisition compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGSTW vs. The Competition

Semper Paratus Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools